IMPATH to list on EASDAQ:
This article was originally published in Clinica
IMPATH, a source of patient-specific cancer diagnostic and prognostic information, is to list on the Brussels-based EASDAQ stock exchange. The New York-based company has a database with over 475,000 analysed cancer cases. "We believe this listing will raise our commercial profile among important European clinical, medical and healthcare management decision-makers - as well as international investors," said Dr Anu Saad, IMPATH's president and CEO. "A major element of our approach is to form key strategic alliances and to identify partnerships and complementary acquisitions in Europe." The company serves over 4,500 physicians in over 1,740 hospitals and 290 oncology practices.
You may also be interested in...
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.